Osteoprotegerin gene rs2073617 and rs3134069 polymorphisms in type 2 diabetes patients and sex-specific rs2073618 polymorphism as a risk factor for diabetic foot

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 4, 2013, Pages 176-182

  Nehring, Piotr ^a   Mrozikiewicz Rakowska, Beata ^a   Sobczyk Kopcioł, Agnieszka ^a   Makowski, Adam ^a   Krasnodebski, Przemysław ^a   Płoski, Rafał ^a   Broda, Grazyna ^b   Karnafel, Waldemar ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Diabetes; Foot; Neuroarthropathy; Osteoprotegerin; Polymorphism

Indexed keywords

OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC FOOT; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; POLYMORPHISM, GENETIC;

EID: 84879624632     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1684     Document Type: Article

References (23)

1. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001; 142: 5050-5055.
2. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med. 2001; 79: 243-253.
3. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1977; 89: 309-319.
4. Arko B, Prezelj J, Komel R, et al. Sequenced variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoprotegerin. J Clin Endocrinol Metab. 2002; 87: 4080-4084.
5. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004; 95: 1046-1057.
6. Bayens G, Doroszewska A, de Freitas, et al. Identification of sex-specific associations between polymorphisms of the osteoprotegerin gene. TNFRSF11B, and Paget's disease of bone. J Bone Miner Res. 2007; 22: 1062-1071.
7. Cundy T, Hegde M, Naot D, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet. 2002; 11: 2119-2127.
8. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002; 347: 175-184.
9. Morinaga T, Nakagawa N, Yasuda H, et al. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. Eur J Biochem. 1998; 254: 685-691.
10. Pitocco D, Zelano G, Gioffrè G, et al. Association between osteoprotegerin C1181G and T245G polymorphisms and diabetic Charcot neuroarthropathy: a case-control study. Diabetes Care. 2009; 32: 1694-1697.
11. Mrozikiewicz-Rakowska B, Krasnodebski P, Karliński M, et al. [Risk factors of lower limb amputation in diabetic foot syndrome]. Leczenie Ran. 2011; 8: 15-20. Polish.
12. Holecki M, Chudek J, Titz-Bober M, et al. Changes of bone mineral density in obese perimenopausal women during 5-year follow-up. Pol Arch Med Wewn. 2012; 122: 139-147.
13. Rumianowska A, Nehring P, Mrozikiewicz-Rakowska B, et al. [Osteoprotegerin - a new marker of therosclerosis helpful in selecting patients at amputation risk?]. Leczenie Ran. 2011; 8: 1-5. Polish.
14. Jeffcoate WJ, Rasmussen LM, Hofbauer LC, Game FL. Medial arteria calcification in diabetes and its relationship to neuropathy. Diabetologia. 2009; 52: 2478-2488.
15. Polakowska M, Piotrowski W. Incidence of diabetes in the Polish population: results of the Multicenter Polish Population Health Status Study - WOBASZ. Pol Arch Med Wewn. 2011; 121: 156-163.
16. International Consensus on the Diabetic Foot and Practical Guidelines on the Management and Prevention of the Diabetic Foot 2007. International Working Group on the Diabetic Foot/Consultative Section of the IDF. Amsterdam, the Netherlands, on DVD.
17. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001; 24: 250-256.
18. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16: 1215.
19. Guldiken S, Taskiran B, Demir M. Role of soluble Fas/Fas ligand pathway and osteoprotegerin levels in patients with diabetic foot. Endocrine Abstracts. 2010; 20: 343.
20. Lajer M, Jorsal A, Tarnow L. Role of osteoprotegerin (OPG) in predicting development of foot ulcer and loss of pulse in type 1 diabetic patients with and without diabetic neuropathy. Diabetologia. 2010; 53: 55-56.
21. Korzon-Burakowska A, Jakóbkiewicz-Banecka J, Fiedosiuk A, et al. Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy. Diabet Med. 2012; 29: 771-775.
22. Adamczyk T, Mizia-Stec K, Mizia M, et al. Biomarkers of calcification and atherosclerosis in patients with degenerative aortic stenosis in relation to concomitant coronary artery disease. Pol Arch Med Wewn. 2012; 122: 14-21.
23. Ozcelik F, Yiginer O, Arslan E, et al. Association between glycemic control and the level of knowledge and disease awareness in type 2 diabetic patients. Pol Arch Med Wewn. 2010; 120: 399-406. Education